Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
Conditions: Plaque Psoriasis Interventions: Drug: Adalimumab Sponsors: Egymedicalpedia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)
Conditions: Axial Spondyloarthritis Interventions: Biological: anti-TRBV9 monoclonal antibody infusions; Other: Placebo infusions; Drug: Adalimumab subcutaneous injection; Other: Placebo subcutaneous injection Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
Conditions: Uveitis Interventions: Drug: Adalimumab Biosimilars Injection; Drug: Corticosteroid; Drug: Immunosuppressive Agents Sponsors: Zhongshan Ophthalmic Center, Sun Yat-sen University; The Eye Hospital of Wenzhou Medical University; The First Affiliated Hospital of Soochow University; Shandong Eye Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Clinical Study With Adalimumab Biosimilar
Conditions: Pharmacokinetics; Safety Issues Interventions: Biological: Humira ® (adalimumab) AC Pen [Reference Product]; Biological: Adalimumab Richmond [Test Product] Sponsors: Laboratorios Richmond S.A.C.I.F.; FP Clinical Pharma S.R.L.; Custom Biologics Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis
Conditions: Ulcerative Colitis; Inflammatory Bowel Diseases Interventions: Drug: Infliximab; Drug: Adalimumab Sponsors: Vastra Gotaland Region Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Conditions: Ulcerative Colitis Interventions: Drug: Lutikizumab Matching Placebo; Drug: Lutikizumab Matching Placebo; Drug: Adalimumab Matching Placebo; Drug: Lutikizumab; Drug: Lutikizumab; Drug: Adalimumab Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Treatment FOr Corticosteroid Dependent UveitiS
Conditions: Non Infectious Uveitis Interventions: Drug: Adalimumab; Drug: Mycophenolate Mofetil Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate 608 in Patients With Ankylosing Spondylitis (AS)
Conditions: Ankylosing Spondylitis Interventions: Drug: 608 Dose A; Drug: 608 Dose B; Drug: 608 Dose C; Drug: Adalimumab; Drug: Placebo Sponsors: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
Conditions: Crohn ' s Disease Interventions: Drug: Strategy A; Drug: Strategy B Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Takeda France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
ATLANTA, Nov. 11, 2023. CB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA (certolizumab pegol) and adalimumab in patients with rheumatoid arthritis (RA) with high... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
Conditions: Crohn Disease; Ulcerative Colitis Interventions: Drug: Adalimumab-680LT; Other: Control Sponsors: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Conditions: Juvenile Psoriatic Arthritis Interventions: Drug: Adalimumab; Drug: Risankizumab Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Effects of TNF Blockade on Human BPH/LUTS
Conditions: Benign Prostatic Hyperplasia (BPH) Interventions: Drug: Adalimumab Sponsors: NorthShore University HealthSystem; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Condition: Crohn's Disease Interventions: Drug: Vedolizumab; Drug: Adalimumab; Drug: Ustekinumab Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
